Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Jyseleca European Launches Could Lift Gloom At Galapagos

The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.

Launches Immune Disorders

Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact

The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.

Gene Therapy Blood & Coagulation Disorders

US Prescribers Embrace Oncology Biosimilars; How Will Humira Follow-Ons Fare?

Rheumatologists may be more cautious about prescribing biosimilars to Humira than they have been for biosimilars to Avastin and Herceptin. But pharmacy benefit managers will have more influence over Humira biosimilars, which adds a new dynamic to the follow-on market.

Biosimilars Market Access

Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings

Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.

Commercial Cancer

More Big Pharma Players Have Access Plans For Poorer Countries

The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.

Market Access Research and Development Strategies

Europe Takes Leap Of Faith On AstraZeneca Vaccine

A conditional marketing authorization for AstraZeneca/Oxford's COVID-19 vaccine came just hours after the European Medicines Agency’s CHMP voted unanimously to recommend it on Friday.

Approvals Coronavirus COVID-19

Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Clinical Trials Coronavirus COVID-19

Multinationals Start 2021 Empty Handed In China National Reimbursement Race

China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.

Commercial Market Access

TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.

BioPharmaceutical Immune Disorders
See All
UsernamePublicRestriction

Register